Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Chin Med J (Engl). 2022 Apr 20;135(8):890-900. doi: 10.1097/CM9.0000000000001898.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the standard of care for adult acute lymphoblastic leukemia (ALL) patients. In recent years, with the continuous development of immunotherapy, such as chimeric antigen receptor T cells, blinatumomab, and inotuzumab ozogamicin, a series of vital clinical studies have confirmed its high response rate and favorable outcomes for ALL. Although the emergence of immunotherapy has expanded relapsed or refractory (r/r) ALL patients' opportunities to receive allo-HSCT, allo-HSCT is associated with potential challenges. In this review, the role of allo-HSCT in the treatment of adult ALL in the era of immunotherapy will be discussed.
异基因造血干细胞移植（allo-HSCT）目前是成人急性淋巴细胞白血病（ALL）患者的标准治疗方法。近年来，随着嵌合抗原受体 T 细胞、blinatumomab 和 inotuzumab ozogamicin 等免疫疗法的不断发展，一系列重要的临床研究证实了其对 ALL 的高反应率和良好疗效。尽管免疫疗法的出现扩大了复发/难治性（r/r）ALL 患者接受 allo-HSCT 的机会，但 allo-HSCT 仍存在潜在挑战。本文将讨论免疫治疗时代 allo-HSCT 在成人 ALL 治疗中的作用。
